Phase lb dose-finding study of axitinib plus pembrolizumab in treatment-naive patients with advanced renal cell carcinoma

被引：0
|
作者：
Choueiri, Toni K. [1 ]
Plimack, Elizabeth R. [2 ]
Gupta, Shilpa [3 ]
Puzanov, Igor [4 ]
Mcdermott, David F. [5 ]
Tarazi, Jamal [6 ]
Keefe, Stephen [7 ]
Rosbrook, Brad [6 ]
Atkins, Michael B. [8 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[3] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[6] Pfizer Oncol, San Diego, CA USA
[7] Merck Res Labs, N Wales, PA USA
[8] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
BJU INTERNATIONAL | 2015年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [41] A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma.
    Zibelman, Matthew R.
    Carducci, Michael Anthony
    Ged, Yasser
    Molina, Ana M.
    Ravilla, Rahul
    Shaffer, David R.
    Lambert, Courtney
    Tafseer, Mahvish
    Basiura, Rachel
    Weismann, Danielle
    Kokate, Rutika
    Devarajan, Karthik
    Ruth, Karen
    Alpaugh, R. Katherine
    Anari, Fern
    Ghatalia, Pooja
    Geynisman, Daniel M.
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [42] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [43] Open-label phase II trial of everolimus monotherapy in treatment-naive patients with advanced papillary renal cell carcinoma
    Caglio, S.
    Slimane, K.
    May, C.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] A Phase I Dose-Finding Study of Silybin Phosphatidylcholine (Milk Thistle) in Patients With Advanced Hepatocellular Carcinoma
    Siegel, Abby B.
    Narayan, Rupa
    Rodriguez, Rosa
    Goyal, Abhishek
    Jacobson, Judith S.
    Kelly, Kara
    Ladas, Elena
    Lunghofer, Paul J.
    Hansen, Ryan J.
    Gustafson, Daniel L.
    Flaig, Thomas W.
    Tsai, Wei Yann
    Wu, David P. H.
    Lee, Valerie
    Greenlee, Heather
    INTEGRATIVE CANCER THERAPIES, 2014, 13 (01) : 46 - 53
  • [45] Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
    Watson, Tina R.
    Gao, Xin
    Reynolds, Kerry L.
    Kong, Chung Yin
    JAMA NETWORK OPEN, 2020, 3 (10)
  • [46] Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naive advanced renal cell carcinoma (RCC)
    Agarwal, N.
    Vaishampayan, U.
    Green, M.
    di Nucci, F.
    Chang, P-Y.
    Scheffold, C.
    Pal, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 308 - 308
  • [47] A COST-EFFCTIVENESS ANALYSIS OF PEMBROLIZUMAB PLUS AXITINIB VERSUS SUNITINIB FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
    Gu, J.
    VALUE IN HEALTH, 2020, 23 : S32 - S32
  • [48] A phase I/Ib, open-label, dose-finding study to evaluate safety, pharmacodynamics, and efficacy of pembrolizumab (MK-3475) in combination with vorinostat in patients with advanced renal or urothelial cell carcinoma
    Pili, Roberto
    Quinn, David
    Hahn, Noah M.
    Albany, Costantine
    Logan, Theodore F.
    Drake, Charles G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (09) : 1507 - 1517
  • [50] Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive Non-Small Cell Lung Cancer (JVDF)
    Herbst, R.
    Arkenau, H.
    Bendell, J.
    Arrowsmith, E.
    Wermke, M.
    Soriano, A.
    Penel, N.
    Santana-Davila, R.
    Bischoff, H.
    Chau, I.
    Chao, B.
    Ferry, D.
    Mi, G.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S307 - S307
12345